Recent Updates
Recently added Catalysts

NextCure, Inc.

NXTCFDA catalysts, PDUFA dates & pipeline intelligence
$6.7
▲ +0.02 · +0.3%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full NXTC financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.5552W HIGH $15.74
Volume
78.17 K
Value Traded
546.04 K
Short % Float
4.8%
Days to Cover
3.0
+12.04%Week
+18.17%1 Month
-1.18%3 Month
-30.53%6 Month
-92.15%5 Year
-95.8%All Time

Cash Data

Unlock NXTC cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
30.68 M
EPS (TTM)
-8.95
P/E Ratio
-
Ent. Value
21.95 M
Total Shares
4.58 M
Float Shares
3.83 M
Insiders
16.30%
Institutions
56.63%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout
LNCB74 (B7-H4 ADC)
Advanced solid tumors, breast and gynecological cancers, adenoid cystic carcinoma type 1
Phase 1Antibody-Drug Conjugates (ADCs)Oncology
Unlock every NXTC catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

NXTC Catalyst Timeline

Dated clinical, regulatory and corporate events for NextCure, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for NextCure, Inc.

319Total events
16Upcoming
61Tier-1 (high impact)
2019 to 2029Coverage

Upcoming catalysts 2

T1Acquisition
Subscribe to view catalyst details
T2Equity Offering
Subscribe to view catalyst details

Event history 50

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results
▲Corporate ApprovalCorporate
SEC declared Form S-4 registration statement effective
▲Legal / SettlementCorporate
Delaware Court of Chancery final order validating July 2025 reverse stock split
●Other Regulator MilestoneLNCB74Ex-US Regulatory
Transfer of LNCB74 IND and regulatory responsibilities to LigaChem completed
●Trial CompletionSIM0505Trial
Completed treatment and transition activities for patients in SIM0505 study
▼Equity OfferingCorporate
Avere Therapeutics announces $500 million private placement
◆AcquisitionCorporate
Xcellon Biologics signs definitive agreement to acquire NextCure's GMP manufacturing facility
●Management ChangeCorporate
Xcellon Biologics appoints Abhishake Chhibber as CEO
▲Partnership / LicenseLNCB74Corporate
Entered into Transition and Continuation Agreement with LigaChem for LNCB74
●Quarterly UpdateCorporate
Reported Q2 2026 financial results
Unlock the full NXTC catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How NXTC actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-05-29SIM0505 Phase 1 data readout Phase 1
Unlock 8 more NXTC historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 87%
Micro Cap
(rank 631 of 725)
Percentile Rank
Showing 2 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
SIM0505 Antibody-Drug Conjugates (ADCs)NCT06792552Advanced Solid TumorsPhase 1 RECRUITING 738Aug 1, 2028
LNCB74 Antibody-Drug Conjugates (ADCs)NCT06774963Ovarian CancerPhase 1 RECRUITING 145Dec 1, 2027
Unlock the NXTC pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every NXTC program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
SIM0505
Fast Track
gynecologic cancersPhase 12026-06-01In a Phase 1 trial of SIM0505 for gynecologic cancers, the drug demonstrated a 55% overall response rate (ORR) at 12 weeks, with 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma, within a therapeutic dose range of 4.8 · 8.0 mg/kg.Read MoreNextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026Read More
Scroll for more · summaries link to the source press release
Unlock every NXTC trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock NXTC insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
ADAR1 Capital Management, LLC10% OwnerBuy 12,333 750,289 held$5.10 11/11/2026
Unlock the full NXTC insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
AFFINITY ASSET ADVISORS, LLC 0.1 % 1.46 M 291.96 K 595.81% ( 250.00 K)
Unlock every fund holding NXTC
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in NXTC
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see NXTC ownership
Insider and institutional ownership, quarter by quarter.

NXTC Short Interest

Shares sold short, counted twice a month.

4.8%
Short % of Float
of tradable shares sold short
184.0K
Shares Sold Short
-16.7% vs prior count
3.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
61.9K
Avg Daily Volume
the average used for days to cover
Unlock NXTC short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock NXTC option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live NXTC option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock NXTC options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How NXTC ranks across every disease it competes in

Competitive Position is a premium feature
See how NXTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

NXTC News

NXTC
Nov 10, 2026
NXTCGeneral

NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results

NextCure, Inc. reported a business update and financial results for Q3 2026, highlighting its proposed merger with Avere Therapeutics. The merger is backed by approximately $820 million in financing, with a stockholder vote set for December 9, 2026. The company also noted significant restructuring efforts and a decrease in cash reserves.

Read more →
NXTC
Aug 10, 2026
NXTCGeneral
▲ +17.1%on this news· ran to +42% by day 3

Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics

Xcellon Biologics has acquired a GMP manufacturing facility from NextCure, enhancing its capabilities as a comprehensive CRDMO for bioconjugates and complex biologics. The facility will support the development of antibody-based therapeutics from discovery to clinical supply. CEO Abhishake Chhibber emphasizes the importance of this acquisition in strengthening the U.S. biotechnology ecosystem.

Read more →
NXTC
Aug 10, 2026
NXTCGeneral
▲ +17.1%on this news· ran to +42% by day 3shared move

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Avere Therapeutics announced a $500 million private placement to fund its operating plan through 2029. This follows a previously announced $320 million concurrent private investment. The combined capital supports the development of AVR-001, a once-weekly oral IL-23 therapy. The company is merging with NextCure in an all-stock transaction expected to close in the second half of 2026.

Read more →
NXTC
Aug 6, 2026
NXTCGeneral

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

NextCure, Inc. announced a proposed merger with Avere Therapeutics, aiming to close in the second half of 2026. The merger is expected to generate approximately $320 million in gross proceeds. Despite a net loss of $14.9 million for Q2 2026, the company is focused on preserving capital and supporting ongoing clinical programs. Restructuring initiatives have been implemented to reduce operating expenses.

Read more →
NXTC
Jul 14, 2026
NXTCGeneral
▲ +201.8%on this news

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

NextCure and Avere Therapeutics have announced a merger to enhance the development of AVR-001, an oral IL-23 therapy for inflammatory diseases. The merger is supported by a $320 million private investment, ensuring sufficient funding for upcoming clinical trials. The combined entity will operate under the name Avere Therapeutics, Inc. and is expected to trade on Nasdaq as AVRX.

Read more →
NXTC
Jun 4, 2026
NXTCConferences/Events

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

NextCure, Inc. announced the replay of its virtual KOL event discussing the promising Phase 1 dose escalation data for SIM0505, an investigational ADC targeting gynecologic cancers. The event featured expert insights on the efficacy of SIM0505 in treating ovarian cancer and uterine serous carcinoma. This follows the ASCO 2026 presentation, where the company shared its first clinical efficacy results.

Read more →
NXTC
Jun 1, 2026
NXTCPhases
▼ -45.5%on this news

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

NextCure presented promising Phase 1 data for SIM0505 at ASCO 2026, showing a 55% objective response rate in gynecologic cancers, including 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma. The therapy demonstrated a favorable safety profile in heavily pretreated patients. NextCure plans to continue dose optimization and will host a virtual KOL event to discuss these results.

Read more →
NXTC
May 7, 2026
NXTCFDA Updates
▼ -5%on this news

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

NextCure, Inc. reported a business update and financial results for Q1 2026, highlighting the Fast Track designation for SIM0505 in treating platinum-resistant ovarian cancer. The company plans to present Phase 1 data at ASCO 2026 and has initiated a dose optimization study. Despite a net loss of $9.8 million, NextCure aims to expand its trial sites into Canada and Europe.

Read more →
NXTC
May 4, 2026
NXTCPhases

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

NextCure and Simcere Zaiming have initiated the dose optimization phase of their Phase 1 study for SIM0505, targeting platinum-resistant ovarian cancer. The investigational ADC aims to finalize dose selection and expand its clinical footprint. Phase 1 data is expected to be presented at ASCO 2026, highlighting the development progress.

Read more →
NXTC
Apr 21, 2026
NXTCPhases
▼ -6.2%on this news

NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

NextCure has announced that Phase 1 data for SIM0505, an investigational antibody drug conjugate targeting CDH6, will be presented at ASCO 2026. This presentation signifies an important milestone in NextCure's collaborative clinical approach and commitment to developing innovative cancer therapies. SIM0505 is currently being evaluated for its effectiveness in treating advanced solid tumors, including platinum-resistant ovarian cancer. The presentation is scheduled for June 1, 2026, in Chicago, Illinois.

Read more →
NXTC
Apr 7, 2026
NXTCFDA Updates

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

NextCure, Inc. has received Fast Track designation from the FDA for SIM0505, an investigational antibody drug conjugate aimed at treating platinum-resistant ovarian cancer. This designation will facilitate closer collaboration with the FDA, expediting the development process. The company plans to initiate dose optimization in Q2 2026 and present Phase 1 data at the ASCO conference in 2026.

Read more →
NXTC
Apr 1, 2026
NXTCConferences/Events

NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

NextCure, Inc. and Simcere Zaiming Pharmaceutical Co., Ltd. have announced that an abstract for their investigational antibody drug conjugate, SIM0505, has been accepted for presentation at the ASCO 2026 meeting. The ongoing Phase 1 study is focused on advanced solid tumors, particularly platinum-resistant ovarian cancer. This development highlights the potential of SIM0505 in cancer treatment.

Read more →
NXTC
Mar 5, 2026
NXTCPhases

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

NextCure, Inc. has announced its business update and 2025 financial results, highlighting its expectations for a transformative 2026 driven by advancements in its SIM0505 program. The company aims to present dose escalation data from a Phase 1 trial and is set to enroll patients for a new study focusing on platinum-resistant ovarian cancer. Despite positive advancements, NextCure faces financial challenges, including a reported net loss and dependency on funding. The development of its antibody-drug conjugates demonstrates potential for impactful cancer therapies amid a backdrop of financial stringency.

Read more →
NXTC
Jan 23, 2026
NXTCPhases
▼ -5.8%on this newsshared move

NextCure Provides Business Update

NextCure reported a preliminary cash balance of $41.8 million as of December 31, 2025. The company expects these funds to cover operating expenses through the first half of 2027. Data for its SIM0505 program is now expected in the second quarter of 2026. Proof-of-concept results for LNCB74 are delayed until the second half of 2026.

Read more →
NXTC
Nov 20, 2025
NXTCConferences/Events

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

NextCure, Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3rd. The event will be held in New York City and will include a live audio webcast available on their website. NextCure focuses on developing innovative cancer therapies, particularly for patients who do not respond to existing treatments.

Read more →
NXTC
Nov 17, 2025
NXTCPhases

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

NextCure, Inc. has successfully closed a $21.5 million private placement in public equity (PIPE), primarily led by several healthcare-focused funds. This financing is intended to bolster NextCure's working capital and ensures that the company's cash runway extends into the first half of 2027, beyond the expected data readouts from their antibody drug conjugate programs in the first half of 2026. The PIPE offering included the issuance of common stock and pre-funded warrants, with H.C. Wainwright & Co. serving as the exclusive placement agent.

Read more →
NXTC
Nov 12, 2025
NXTCGeneral
▲ +9%on this news· ran to +19% by day 3shared move

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

NextCure, Inc. has announced a private placement of common stock, raising approximately $21.5 million. The offering, priced at $8.52 per share, involves institutional investors and is expected to close on November 13, 2025. The funds will be used for general working capital and to support ongoing clinical programs, extending the company's cash runway into the first half of 2027.

Read more →
NXTC
Nov 5, 2025
NXTCPhases

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

NextCure reported a net loss of $8.6 million for the third quarter of 2025. Cash and marketable securities stood at $29.1 million as of September 30, 2025. The company began U.S. enrollment for its SIM0505 Phase 1 trial. It also received FDA clearance to add higher dose cohorts for its LNCB74 program.

Read more →
NXTC
Oct 16, 2025
NXTCPhases
▲ +27.8%on this news· ran to +75% by day 1

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

NextCure, Inc. and Simcere Zaiming have announced the dosing of the first patient in the U.S. as part of the ongoing Phase 1 trial of SIM0505, an antibody drug conjugate targeting advanced solid tumors. The trial, initially launched in China, is now expanding to include U.S. patients, with promising safety and efficacy data reported. The companies aim to present proof-of-concept data in the first half of 2026.

Read more →
NXTC
Sep 4, 2025
NXTCConferences/Events

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NextCure, Inc. will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8th, 2025. The event will be accessible via a live audio webcast on the company's website. NextCure is dedicated to developing innovative therapies for cancer patients who do not respond to existing treatments.

Read more →

About NextCure, Inc.

Baltimore, MD 40 employees nextcure.com
Headquarters2850 QUARRY LAKE DRIVE, BALTIMORE, MD, 21209
BIOPHARMAWATCH ELITE
Trade the next NXTC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime